Helokinestatin: a new bradykinin B2 receptor antagonist decapeptide from lizard venom.

H.F. Kwok, Tianbao Chen, M. O’Rourke, C. Ivanyi, David Hirst, Christopher Shaw

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Synthetic bradykinin antagonist peptides/peptoids have been powerful tools for delineating the roles of kinins in both normal physiology and in pathological states. Here, we report the identification of a novel, naturally occurring bradykinin B2 receptor antagonist peptide, helokinestatin, isolated and structurally characterized from the venoms of helodermatid lizards—the Gila monster (Heloderma suspectum) and the Mexican beaded lizard (Heloderma horridum). The primary structure of the peptide was established by a combination of microsequencing and mass spectroscopy as Gly-Pro-Pro-Tyr-Gln-Pro-Leu-Val-Pro-Arg (Mr 1122.62). A synthetic replicate of helokinestatin was found to inhibit bradykinin-induced vasorelaxation of phenylephrine pre-constricted rat tail artery smooth muscle, mediated by the B2 receptor sub-type, in a dose-dependent manner. Natural selection, that generates functional optimization of predatory reptile venom peptides, can potentially provide new insights for drug lead design or for normal physiological or pathophysiological processes.
Original languageEnglish
Pages (from-to)65-72
Number of pages8
Volume29 (1)
Issue number1
Publication statusPublished - Jan 2008

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Helokinestatin: a new bradykinin B2 receptor antagonist decapeptide from lizard venom.'. Together they form a unique fingerprint.

Cite this